Ronny Meglin hat seine Doktorarbeit erfolgreich verteidigt. – Nachh...
... of a Regional Construction and Building Materials Industry in Switzerland: An Applied Combination of ... Industry in Switzerland: An Applied Combination of Material-Flow Analysis, Life-Cycle Assessment and Input ...
https://new.usz.ch/fachbereich/comprehensive-cancer-center-zuerich/...
... , NSCLC, PRC; UCC; RCC, TNBC, CC, Melanoma) Offizieller Titel A Phase 1/2 Dose Escalation and Combination ... -ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid Tumors ...
Solide Tumoren – UniversitätsSpital Zürich
... Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability ... , Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab ... Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and ... Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients ...
Solide Tumoren – UniversitätsSpital Zürich
... Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability ... , Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab ... Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and ... Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients ...
https://new.usz.ch/fachbereich/comprehensive-cancer-center-zuerich/...
... of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel ... in Combination With HER2 Blockade for Elderly Patients With Hormone Receptor Positive/HER2 Positive ...
https://new.usz.ch/fachbereich/comprehensive-cancer-center-zuerich/...
... Melanompatienten Stadium Fortgeschrittener Nierenkrebs Offizieller Titel Nivolumab in combination with Ipilimumab ... Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid ...
Brustkrebs – UniversitätsSpital Zürich
... Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus ... Paclitaxel in Combination With HER2 Blockade for Elderly Patients With Hormone Receptor Positive/HER2 ... Offizieller Titel Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination ... With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Elderly ...
Brustkrebs – UniversitätsSpital Zürich
... Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus ... Paclitaxel in Combination With HER2 Blockade for Elderly Patients With Hormone Receptor Positive/HER2 ... Offizieller Titel Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination ... With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Elderly ...
Phase-I Studien – Universitätsspital Zürich
... efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) administered alone and in combination with Anti-PD ... Combination With Nivolumab in Advanced Cancers Kurzbeschreibung Eine Phase-1/2a Studie zum monoklonalen ... of Anti-LAG-3 Monoclonal Antibody (BMS-986016) administered alone and in combination with Anti-PD-1 ... of BMS-986253 in Combination With Nivolumab in Advanced Cancers Kurzbeschreibung Eine Phase-1/2a ...
https://new.usz.ch/fachbereich/comprehensive-cancer-center-zuerich/...
... Cabozantinib (XLl84) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular ... Randomized, Open-label Phase II Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus ...
